Xeno is a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.
Xeno is developing a first-in-class pharmacotherapy to mimic the surgery-induced microbiome shift and weight loss from Gastric Bypass Surgery.
XEN-101, Xeno's lead product candidate, is an oral-pill formulation designed to deliver molecular oxygen to the lower gut, and thereby mimic the microbiome shift and weight loss induced by Roux-en-Y Gastric Bypass (RYGB) surgery.
To date, XEN-101 has shown profound weight loss efficacy in human subjects and animal models.
Location: United States, Massachusetts, Cambridge
Investors 7
Mentions in press and media 2
| Date | Title | Description | Source |
| 19.06.2018 | 15 Boston Microbiome Startups to Watch | “Bacteria, it’s the only culture some people have!” If you spot someone wearing a tee shirt with th... | bizjournal... |
| - | Xeno Biosciences | “Xeno Biosciences” | fastfounde... |